Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04470934
Other study ID # AAG-O-H-1913
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 30, 2021
Est. completion date December 31, 2025

Study information

Verified date February 2023
Source B. Braun Melsungen AG
Contact Sylvia Otto, MD
Phone +49 3641 932 45 60
Email Sylvia.Otto@med.uni-jena.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to assess continued safety and efficacy of the SeQuent® SCB. The product under investigation will be used in routine clinical practice according to the latest European Society of Cardiology (ESC) guidelines and according to the Instructions for Use (IFU). Those data that are obtained in routine clinical use will be documented in the Case Report Form (CRF).


Description:

The objective of the study is to assess the continued safety and efficacy of SeQuent® SCB for the treatment of "real world" de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts. Study goals are based on non-inferiority for Drug-Coated Balloon (DCB) compared to Paclitaxel-Coated Balloon (PCB) and Dru-eluting Stents (DES) (historical data) with 80% power. Primary and secondary outcome variables are international accepted parameters in stent-trials, which sufficiently describe the efficacy and safety of the investigated device and allow clinical conclusions. Additional attention will be paid to those patients who received, by observation, a shortened dual antiplatelet therapy (DAPT). The aim of the study is to assess the safety and efficacy of the SeQuent® SCB in the treatment of coronary artery disease with reference vessel diameters between ≥ 2 mm and ≤ 4 mm with suitable lesion lengths. There is no limitation of lesion lengths. In case the lesion is longer than 34 mm, more than one stent needs to be used.


Recruitment information / eligibility

Status Recruiting
Enrollment 1302
Est. completion date December 31, 2025
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All common significant coronary lesions - Target lesion length >34mm need to be covered with at least 2 devices - Patients eligible for this study must be at least 18 years of age - The patient must fulfil the standard recommendations for percutaneous coronary intervention (PCI), based on the last ESC recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment Exclusion Criteria: - Intolerance to sirolimus - Allergy to components of the coating - Pregnancy and lactation - Complete occlusion of the treatment vessel because of an unsuccessfully re-canalized - Cardiogenic shock - Risk of an intraluminal thrombus - Hemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anti-coagulation therapy - Surgery shortly after myocardial infarction with indications of thrombus or poor coronary flow behavior - Severe allergy to contrast media - Lesions which are untreatable with PCI or other interventional techniques - Patients with an ejection fraction of < 30 % - Vascular reference diameter < 2.00 mm - Treatment of the left stem (first section of the left coronary artery) - Indication for a bypass surgery - Contraindication for whichever accompanying medication is necessary

Study Design


Intervention

Device:
SeQuent® SCB drug-coated balloon catheter
treatment of coronary artery disease with SeQuent® SCB of "real world" de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts

Locations

Country Name City State
Germany Universitätsklinikum Jena Jena Thüringen

Sponsors (1)

Lead Sponsor Collaborator
B. Braun Melsungen AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Target Lesion Failure (TLF) Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR). at 12 months
Secondary Target Lesion Failure (TLF) Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR). at 24 months
Secondary ischemia driven target lesion revascularization (TLR) at 12 months
Secondary ischemia driven target lesion revascularization (TLR) at 24 months
Secondary all-cause death, cardiac death at 12 months
Secondary all-cause death, cardiac death at 24 months
Secondary all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI) at 12 months
Secondary all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI) at 24 months
Secondary major adverse coronary event (MACE) major adverse coronary event (MACE): defined as composite of cardiovascular death, myocardial infarction or ischemia-driven target lesion revascularization at 12 months
Secondary major adverse coronary event (MACE) major adverse coronary event (MACE): defined as composite of cardiovascular death, myocardial infarction or ischemia-driven target lesion revascularization at 24 months
Secondary Dual Antiplatelet Therapy (DAPT) compliance at 4 weeks
Secondary Dual Antiplatelet Therapy (DAPT) compliance at 3 months
Secondary Probable or definite stent-thrombosis of In-stent treated lesions accumulated at 12 months
Secondary Probable or definite stent-thrombosis of In-stent treated lesions accumulated at 24 months
Secondary Procedural success final diameter stenosis < 30 % without flow-limiting dissections immediately after procedure
Secondary Bleeding complications according to the Bleeding Academic Research Consortium (BARC) accumulated at 3 months
Secondary Bleeding complications according to the Bleeding Academic Research Consortium (BARC) accumulated at 12 months
Secondary Bleeding complications according to the Bleeding Academic Research Consortium (BARC) accumulated at 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A